ACADIA Pharmaceuticals Inc
$ 21.56
-0.74%
05 Jun - close price
- Market Cap 3,719,243,000 USD
- Current Price $ 21.56
- High / Low $ 21.96 / 21.45
- Stock P/E 9.83
- Book Value 7.29
- EPS 2.21
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.37 %
- 52 Week High 28.35
- 52 Week Low 19.69
About
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
Analyst Target Price
$31.65
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-06 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-02 |
| Reported EPS | 0.02 | 0.1375 | 0.42 | 0.16 | 0.11 | 0.86 | 0.2 | 0.2 | 0.1 | 0.28 | -0.4 | 0.01 |
| Estimated EPS | 0.08 | 0.1389 | 0.15 | 0.14 | 0.11 | 0.219 | 0.14 | 0.18 | 0.06 | 0.3 | -0.42 | -0.12 |
| Surprise | -0.06 | -0.0014 | 0.27 | 0.02 | 0 | 0.641 | 0.06 | 0.02 | 0.04 | -0.02 | 0.02 | 0.13 |
| Surprise Percentage | -75% | -1.0079% | 180% | 14.2857% | 0% | 292.6941% | 42.8571% | 11.1111% | 66.6667% | -6.6667% | 4.7619% | 108.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACAD
2026-06-05 04:39:05
The article from MSN has no content and therefore cannot be summarized. It appears to be an empty or placeholder article about ACADIA Pharmaceuticals and its pipeline for Alzheimer's psychosis, including NUPLAZID and DAYBUE. No further details are available.
2026-06-02 20:51:10
Baker Bros. Advisors LP reported acquisition or exercise transactions for ACADIA PHARMACEUTICALS INC, including 18,622 restricted stock units and 32,008 non-qualified stock options. These grants are linked to board service by Julian C. Baker and Dr. Stephen R. Biggar, with the Baker funds holding an indirect pecuniary interest. The stock options have a strike price of $21.66 and vest in quarterly installments starting May 29, 2026.
2026-06-02 12:09:19
The article analyzes Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) using AI models, highlighting divergent sentiment across trading horizons indicating choppiness. It presents institutional trading strategies for different risk profiles, including a long position, a momentum breakout, and a risk-hedging short position, alongside multi-timeframe signal analysis with specific support and resistance levels. The report emphasizes a significant risk-reward setup targeting a 14.0% gain versus 0.3% risk.
2026-06-02 08:41:04
ACADIA Pharmaceuticals director James M. Daly reported equity compensation activities on May 29, 2026. He exercised 8,107 previously granted restricted stock units and was subsequently granted 9,311 new restricted stock units and 16,004 director stock options with an exercise price of $21.66. After these transactions, Daly directly holds 12,148 common shares.
2026-06-02 06:09:19
This article provides an analysis of ACADIA Pharmaceuticals Inc.'s (ACAD) financials, focusing on its revenue breakdown, profitability margins, and competitive positioning. NUPLAZID is identified as the largest revenue contributor, and the company's gross margin is highlighted at 90.75%, contrasting with its operating and net margins. The piece also benchmarks ACAD against industry competitors like KNSA and CRNX.
2026-06-01 21:40:48
ACADIA Pharmaceuticals Inc. director Jonathan Poole reported equity compensation activity in a recent Form 4 filing. He exercised derivative securities for 2,010 shares of common stock, and also received grants of 9,311 restricted stock units (RSUs) and 16,004 director stock options. These transactions represent routine director compensation rather than open-market trading.
